FAQ

alicaforsen

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1997-2017
02419972017

Related topics

Related topics

6 relations

Broader (4)

Antisense OligonucleotidesGastrointestinal AgentsImmunosuppressive AgentsPhosphorothioate Oligonucleotides

Narrower (2)

ISIS 2302alicaforsen sodium

Related mentions per year

Related mentions per year

1951-2018
1960198020002020
alicaforsen
Immunosuppressive Agents
Antisense Oligonucleotides
Gastrointestinal Agents
ISIS 2302
Phosphorothioate Oligonucleotides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series.
BACKGROUND AND AIMS The published data about the efficacy of the intercellular adhesion molecule-1 (ICAM-1) antisense… (More)
Is this relevant?
2013
2013
Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis.
BACKGROUND The antisense ICAM-1 inhibitor alicaforsen has been studied in four phase 2 studies in ulcerative colitis (UC… (More)
Is this relevant?
2007
2007
A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.
BACKGROUND & AIMS The aim of this study was to compare the safety and efficacy of alicaforsen, a first-generation antisense… (More)
Is this relevant?
2006
2006
Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.
BACKGROUND Alicaforsen is a phosphorothioate-modified antisense oligodeoxynucleotide designed to sequence-specifically reduce… (More)
Is this relevant?
Review
2005
Review
2005
Technology evaluation: alicaforsen (Isis).
Isis is developing alicaforsen, an RNase H-dependent antisense inhibitor of intercellular adhesion molecule-1, for the potential… (More)
Is this relevant?
2004
2004
An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis.
BACKGROUND Pouchitis is the major long-term complication of ileal pouch-anal anastomosis for ulcerative colitis. The incidence of… (More)
Is this relevant?
2004
2004
INFLAMMATORY BOWEL DISEASE A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis
Objective: To evaluate the safety and efficacy of an enema formulation of alicaforsen, an antisense inhibitor of intercellular… (More)
  • table 2
  • table 1
  • figure 1
  • figure 2
  • figure 1
Is this relevant?
2002
2002
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn…
BACKGROUND AND AIMS To evaluate the safety and efficacy of the intercellular adhesion molecule 1 (ICAM-1) antisense… (More)
Is this relevant?
2002
2002
Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
BACKGROUND AND AIMS To evaluate the safety, pharmacokinetics and clinical efficacy of the intercellular adhesion molecule-1… (More)
Is this relevant?
Review
2001
Review
2001
Alicaforsen. Isis Pharmaceuticals.
Alicaforsen (ISIS-2302) is an RNase H-dependent antisense inhibitor of the intercellular adhesion molecule ICAM-1 under… (More)
Is this relevant?